Interleukin-8 reduces post-surgical lymphedema formation by promoting lymphatic vessel regeneration

Angiogenesis

Volumn 16, Issue 1, 2013, Pages 29-44

  Choi, Inho ^a,b,d   Lee, Yong Suk ^a,b   Chung, Hee Kyoung ^a,b   Choi, Dongwon ^a,b   Ecoiffier, Tatiana ^e   Lee, Ha Neul ^a,b   Kim, Kyu Eui ^a,b   Lee, Sunju ^a,b   Park, Eun Kyung ^a,b   Maeng, Yong Sun ^a,b   Kim, Nam Yun ^a,b   Ladner, Robert D ^b,c   Petasis, Nicos A ^b,c   Koh, Chester J ^c   Chen, Lu ^e   Lenz, Heinz Josef ^b,c   Hong, Young Kwon ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Hoseo University   (South Korea)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Interleukin 8; Lymphangiogenesis; Lymphatic endothelial cells; Lymphedema; Prox1

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1C; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 8; MATRIGEL; PROTEIN PROX1; REGULATOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ASSAY; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORNEA; DISEASE COURSE; EMBRYO; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; ENDOTHELIUM CELL TUBE FORMATION; ENZYME REPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; LYMPHEDEMA; MOUSE; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P57; DOWN-REGULATION; EMBRYONIC DEVELOPMENT; ENDOTHELIAL CELLS; HOMEODOMAIN PROTEINS; HUMANS; INTERLEUKIN-8; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; LYMPHEDEMA; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PHYSIOLOGIC; POSTOPERATIVE COMPLICATIONS; RECEPTORS, INTERLEUKIN-8; RECEPTORS, INTERLEUKIN-8A; RECEPTORS, INTERLEUKIN-8B; REGENERATION; TRETINOIN; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 84871615440     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-012-9297-6     Document Type: Article

References (57)

1. Oliver G, Alitalo K (2005) The lymphatic vasculature: recent progress and paradigms. Annu Rev Cell Dev Biol 21:457-483
2. Norrmen C et al (2011) Biological basis of therapeutic lymphangiogenesis. Circulation 123(12):1335-1351
3. Schmitz KH et al (2012) Prevalence of breast cancer treatment sequelae over 6 years of follow-up: the pulling through study. Cancer 118(8 Suppl):2217-2225
4. Shimoda H, Bernas MJ, Witte MH (2011) Dysmorphogenesis of lymph nodes in Foxc2 haploinsufficient mice. Histochem Cell Biol 135(6):603-613
5. Shah C, Vicini FA (2011) Breast cancer-related arm lymphedema: incidence rates, diagnostic techniques, optimal management and risk reduction strategies. Int J Radiat Oncol Biol Phys 81(4):907-914
6. Warren AG et al (2007) Lymphedema: a comprehensive review. Ann Plast Surg 59(4):464-472
7. Petrek JA et al (2001) Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 92(6):1368-1377
8. Hardin R, Jacobs LK (2012) Lymphedema: still a problem without an answer. Oncology (Williston Park) 26(3):256-257
9. McLaughlin SA (2012) Lymphedema: separating fact from fiction. Oncology (Williston Park) 26(3):242-249
10. Tammela T, Alitalo K (2010) Lymphangiogenesis: molecular mechanisms and future promise. Cell 140(4):460-476
11. Oh SJ et al (1997) VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol 188(1):96-109
12. Hong YK et al (2004) VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. FASEB J 18(10):1111-1113
13. Nagy JA et al (2002) Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med 196(11):1497-1506
14. Nagy JA et al (2002) VEGF-A induces angiogenesis, arteriogenesis, lymphangiogenesis, and vascular malformations. Cold Spring Harb Symp Quant Biol 67:227-237
15. Nakao S et al (2010) Lymphangiogenesis and angiogenesis: concurrence and/or dependence? Studies in inbred mouse strains. FASEB J 24(2):504-513
16. Shin JW et al (2006) Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis. Mol Biol Cell 17(2):576-584
17. Cao R et al (2004) PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 6(4):333-345
18. Kajiya K et al (2005) Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J 24(16):2885-2895
19. Banziger-Tobler NE et al (2008) Growth hormone promotes lymphangiogenesis. Am J Pathol 173(2):586-597
20. Bjorndahl M et al (2005) Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci USA 102(43):15593-15598
21. Koch AE et al (1992) Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258(5089):1798-1801
22. Strieter RM et al (1992) Interleukin-8. A corneal factor that induces neovascularization. Am J Pathol 141(6):1279-1284
23. Simonini A et al (2000) IL-8 is an angiogenic factor in human coronary atherectomy tissue. Circulation 101(13):1519-1526
24. Martin D, Galisteo R, Gutkind JS (2009) CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem 284(10):6038-6042
25. Murdoch C, Monk PN, Finn A (1999) Cxc chemokine receptor expression on human endothelial cells. Cytokine 11(9):704-712
26. Li A et al (2003) IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 170(6):3369-3376
27. Choi I et al (2012) 9-cis retinoic acid promotes lymphangiogenesis and enhances lymphatic vessel regeneration: therapeutic implications of 9-cis retinoic Acid for secondary lymphedema. Circulation 125(7):872-882
28. White JR et al (1998) Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 273(17):10095-10098
29. Kubo K et al (2005) Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. J Med Chem 48(5):1359-1366
30. Kirkin V et al (2004) MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo. Int J Cancer 112(6):986-993
31. Baxter SA et al (2011) Regulation of the lymphatic endothelial cell cycle by the PROX1 homeodomain protein. Biochim Biophys Acta 1813(1):201-212
32. Lee S et al (2009) Prox1 physically and functionally interacts with COUP-TFII to specify lymphatic endothelial cell fate. Blood 113(8):1856-1859
33. Choi I et al (2011) Visualization of lymphatic vessels by Prox1-promoter directed GFP reporter in a bacterial artificial chromosome-based transgenic mouse. Blood 117(1):362-365
34. Wang X et al (1997) Transgenic studies with a keratin promoter-driven growth hormone transgene: prospects for gene therapy. Proc Natl Acad Sci U S A 94(1):219-226
35. Barlic J, Murphy PM (2007) Chemokine regulation of atherosclerosis. J Leukoc Biol 82(2):226-236
36. Bozic CR et al (1994) The murine interleukin 8 type B receptor homologue and its ligands. Expression and biological characterization. J Biol Chem 269(47):29355-29358
37. Starckx S et al (2002) Recombinant mouse granulocyte chemotactic protein-2: production in bacteria, characterization, and systemic effects on leukocytes. J Interferon Cytokine Res 22(9):965-974
38. Waugh DJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14(21):6735-6741
39. Kunstfeld R et al (2004) Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood 104(4):1048-1057
40. Rutkowski JM et al (2006) Secondary lymphedema in the mouse tail: lymphatic hyperplasia, VEGF-C upregulation, and the protective role of MMP-9. Microvasc Res 72(3):161-171
41. Petrova TV et al (2002) Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J 21(17):4593-4599
42. Hirakawa S et al (2003) Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol 162(2):575-586
43. Hong YK et al (2002) Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. Dev Dyn 225(3):351-357
44. Mu H et al (2012) Lysophosphatidic Acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells. Am J Pathol 180(5):2170-2181
45. Wigle JT et al (1999) Prox1 function is crucial for mouse lens-fibre elongation. Nat Genet 21(3):318-322
46. Dyer MA (2003) Regulation of proliferation, cell fate specification and differentiation by the homeodomain proteins Prox1, Six3, and Chx10 in the developing retina. Cell Cycle 2(4):350-357
47. Dyer MA et al (2003) Prox1 function controls progenitor cell proliferation and horizontal cell genesis in the mammalian retina. Nat Genet 34(1):53-58
48. Pan MR et al (2009) Sumoylation of Prox1 controls its ability to induce VEGFR3 expression and lymphatic phenotypes in endothelial cells. J Cell Sci 122(Pt 18):3358-3364
49. Kang J et al (2010) An exquisite cross-control mechanism among endothelial cell fate regulators directs the plasticity and heterogeneity of lymphatic endothelial cells. Blood 116(1):140-150
50. Nelson JD, Denisenko O, Bomsztyk K (2006) Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat Protoc 1(1):179-185
51. Zhang H et al (2011) Spontaneous lymphatic vessel formation and regression in the murine cornea. Invest Ophthalmol Vis Sci 52(1):334-338
52. Bos FL et al (2011) CCBE1 is essential for mammalian lymphatic vascular development and enhances the lymphangiogenic effect of vascular endothelial growth factor-C in vivo. Circ Res 109(5):486-491
53. Cao R et al (2011) Mouse corneal lymphangiogenesis model. Nat Protoc 6(6):817-826
54. Caunt M et al (2008) Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 13(4):331-342
55. Kubo H et al (2002) Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci USA 99(13):8868-8873
56. Ecoiffier T, Yuen D, Chen L (2010) Differential distribution of blood and lymphatic vessels in the murine cornea. Invest Ophthalmol Vis Sci 51(5):2436-2440
57. Vassar R, Rosenberg M, Ross S, Tyner A, Fuchs E (1989) Tissue-specific and differentiation-specific expression of a human K14 keratin gene in transgenic mice. Proc Natl Acad Sci USA 86(5):1563-1567